LeadStory

CNBC

Amgen CEO talks trial results of cardiac drug Repatha

CNBC · Just In
CNBC
CNBC
Just In

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.

Breakdown
  • No level of cholesterol is considered good, and only specific drugs can reduce it to insignificant levels.
  • Repatha lowered LDL cholesterol to a median of 45 and reduced the risk of a first heart attack by 36% in trial subjects. 16s
  • Adding Repatha to optimized therapy prevented first occurrences of heart attack by 36%, reduced stroke risk, and showed a strong signal for preventing cardiac death. 35s
  • The trial definitively answered that lower LDL cholesterol is better, with a median of 45 providing meaningful benefit over placebo in patients already on optimal therapy. 1m 13s
HealthMedical Research